Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals

Hovland, Anders; Nestvold, Torunn Kristin; Bohov, Pavol; Trøseid, Marius; Aukrust, Pål; Berge, Rolf K.; Waage-Nielsen, Erik; Retterstøl, Kjetil; Lappegård, Knut Tore

doi:10.1080/00365513.2017.1393691

Cited by 9 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to other studies [21,22], we did not find significant differences between the amount of SFAs in serum after bariatric surgery, suggesting that OAGB-induced weight loss does not influence this group. The proportion of MUFAs in patients with obesity was significantly higher than in lean controls and this persisted after OAGB.…”

Section: Discussioncontrasting

confidence: 99%

The Effects of One-Anastomosis Gastric Bypass on Fatty Acids in the Serum of Patients with Morbid Obesity

et al. 2021

View full text Add to dashboard Cite

Purpose Obesity is associated with alterations in serum fatty acid profiles. One-anastomosis gastric bypass is a type of bariatric surgery used in the treatment of morbid obesity. The aim of this study was to establish if, between 6 and 9 months after this procedure, the fatty acid composition in the serum of patients normalizes to values similar to the healthy, lean population. Materials/Methods The study included 46 patients that underwent surgical treatment for obesity with one-anastomosis gastric bypass. The serum fatty acid composition was determined using gas chromatography-mass spectrometry. Principal component analysis was conducted to detect the differences between fatty acid profiles in patients pre- and post-surgery, and in 29 control nonobese subjects. Results Patients with morbid obesity were characterized by lowered levels of beneficial odd- and branched-chain fatty acids and polyunsaturated fatty acids. While the odd- and branched-chain fatty acid amounts normalized 6–9 months after bariatric treatment, the polyunsaturated fatty acid levels did not. Moreover, the total fatty acid profiles of patients pre- and post-bariatric surgery were still markedly different than those of lean, healthy controls. Conclusion Following one-anastomosis gastric bypass, there are some beneficial changes in serum fatty acids in treated patients, possibly due to weight loss and dietary regimen changes. However, they may be insufficient to restore the proper levels of other fatty acids, which may need to be additionally supplemented. Graphical abstract

show abstract

Section: Discussioncontrasting

confidence: 99%

The Effects of One-Anastomosis Gastric Bypass on Fatty Acids in the Serum of Patients with Morbid Obesity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several studies have reported on proportional changes in PUFAs (as opposed to absolute concentrations as reported in the current study) and observed that, although absolute concentrations of these fatty acids decreased, relative proportions were actually increased following metabolic surgery, thus creating a more favourable lipid profile [29,48,51]. In the study by Walle et al, however, subjects were instructed to consume 3 teaspoons of rapeseed oil and 6 tea spoons of mainly rapeseed oil based spreads daily for at least 1e2 years after their weight loss operation and were instructed to consume fish 2e3 times a week.…”

Section: Discussionmentioning

confidence: 48%

The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids

et al. 2021

View full text Add to dashboard Cite

Background & aims: Duodenal-jejunal bypass liners (DJBLs) prevent absorption in the proximal small intestine, the site of fatty acid absorption. We sought to investigate the effects of a DJBL on blood concentrations of essential fatty acids (EFAs) and bioactive polyunsaturated fatty acids (PUFAs). Methods: Sub-study of a multicentre, randomised, controlled trial with two treatment groups. Patients aged 18e65 years with type-2 diabetes mellitus and body mass index 30e50 kg/m 2 were randomised to receive a DJBL for 12 months or best medical therapy, diet and exercise. Whole plasma PUFA concentrations were determined at baseline, 10 days, 6 and 11.5 months; data were available for n ¼ 70 patients per group. Results: Weight loss was significantly greater in the DJBL group compared to controls after 11.5 months: total body weight loss 11.3 ± 5.3% versus 6.0 ± 5.7% (mean difference [95% CI] ¼ 5.27% [3.75, 6.80], p < 0.001). Absolute concentrations of both EFAs, linoleic acid and a-linolenic acid, and their bioactive derivatives, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, were significantly lower in the DJBL group than in the control group at 6 and 11.5 months follow-up. Total serum cholesterol, LDL-cholesterol and HDL-cholesterol were also significantly lower in the DJBL group. Conclusion: One year of DJBL therapy is associated with superior weight loss and greater reductions in total serum cholesterol and LDL-cholesterol, but also depletion of EFAs and their longer chain derivatives. DJBL therapy may need to be offset by maintaining an adequate dietary intake of PUFAs or by supplementation. Trial registration: ClinicalTrials.gov Identifier NCT02459561.

show abstract

“…Recent studies have also demonstrated decreased levels of the nephrotoxic lipid species mentioned above. Fatty acid profiles are improved 1 year following bariatric surgery, with decreased saturated fatty acids and increased levels of anti-atherogenic polyunsaturated fatty acids (70,71). Interestingly, in the immediate months following bariatric surgery, a transient increase in serum fatty acids has been observed, which may represent augmented lipolysis and mobilization of fatty acids from adipose tissue and other organs (72)(73)(74).…”

Section: B Improvement In Metabolic and Lipid Factorsmentioning

confidence: 99%

Bariatric surgery and kidney disease outcomes in severely obese youth

Bjornstad¹,

Nehus

Raalte

2020

Seminars in Pediatric Surgery

View full text Add to dashboard Cite

Bariatric surgery, an emerging treatment for severely obese youth with and without T2D, provides marked improvement in insulin resistance, beta-cell function, and central adiposity. Further, preliminary data suggest that bariatric surgery also results in significant improvement in markers of obesity-related nephropathy and DKD, beyond that which can be achieved with current medical interventions. Yet, the mechanisms whereby bariatric surgery attenuates kidney disease remain unclear. This review summarizes the data on the effects of bariatric surgery on obesity-related nephropathy and DKD in youth with and without T2D, in addition to potential mechanisms underlying the nephroprotective effects of weight loss surgery and how these may differ in Rouxen-Y gastric bypass vs. vertical sleeve gastrectomy. Finally, we discuss potential future nonsurgical therapies to mitigate kidney disease.

show abstract

Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals

Abstract: Our findings suggest that a reduced proportion of the proposed anti-atherogenic n-3 PUFAs characterizes morbidly obese individuals, and that this FA profile is reversed by bariatric surgery, but not by lifestyle intervention.

Cited by 9 publications

References 34 publications

The Effects of One-Anastomosis Gastric Bypass on Fatty Acids in the Serum of Patients with Morbid Obesity

The Effects of One-Anastomosis Gastric Bypass on Fatty Acids in the Serum of Patients with Morbid Obesity

The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids

Bariatric surgery and kidney disease outcomes in severely obese youth

Contact Info

Product

Resources

About